A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms STYLE
- Sponsors Celgene Corporation
- 28 Feb 2018 Planned End Date changed from 19 Mar 2019 to 28 Dec 2018.
- 28 Feb 2018 Planned primary completion date changed from 18 Oct 2018 to 18 Jul 2018.
- 08 Jan 2018 According to a Celgene Corporation media release, the company expects to report the data from the trial in 2018.